Berna Singin

Berna Singin

Auto-generated profile, based on publicly available information

Berna Singin

Department of Pediatric Endocrinology, Faculty of Medicine , Akdeniz University , Antalya , Türkiye

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2024 in Journal of Endocrinological Investigation
Verified
Journal Article
Open access
PDF file
YÖY. Özer
Y. Özer
AAAhmet Anık
Ahmet Anık
USUgurcan Sayili
Ugurcan Sayili
UTU. Tercan
U. Tercan
RSR. Deveci Sevim
R. Deveci Sevim
OEOlcay Evliyaoglu
Olcay Evliyaoglu
Purpose: We aimed to determine the frequency of transient congenital hypothyroidism (TCH) in 17 participating centers in Türkiye, evaluate the etiological distribution in permanent congenital hypothyroidism (PCH) cases, and investigate the role of laboratory and clinical findings in predicting TCH. Methods: This retrospective observational multicenter study included patients from 17 pediatric endocrinology centers identified by “National Newborn Screening Program” (NNSP) who were born in 2015 and followed for 6 years. Demographic, clinical, and laboratory information of the cases were compiled through the database http://cedd.saglik-network.org (CEDD-NET). Results: Of the 239 cases initially treated for CH, 128 (53.6%) were determined as transient in whom a trial of levothyroxine (LT4) withdrawal was performed at a median age of 36 (34–38) months. Among the patients with PCH (n = 111), thyroid dysgenesis was diagnosed in 39.6% (n = 44). The predictive factors for TCH were: LT4 dose at the withdrawal of treatment, and initial newborn blood screening (NBS)-TSH level. Based on the receiver operating characteristic (ROC) curve analysis to predict optimal cut-offs for TCH predictors, LT4 dose < 2.0 µg/kg/day at treatment discontinuation was predictive for TCH and was associated with 94.5% specificity and 55.7% sensitivity, with an area under the curve (AUC) of 0.802. The initial NBS-TSH level value < 45 µIU/mL was predictive for TCH with 93.1% specificity and 45.5% sensitivity, with an AUC of 0.641. In patients with eutopic thyroid gland only LT4 dose < 1.1 µg/kg/day at withdrawal time was predictive for TCH with 84.7% sensitivity and 40.4% specificity, with an AUC of 0.750. Conclusion: According to our national follow-up data, the frequency of TCH was 53.6%. We determined the LT4 dose < 2.0 µg/kg/day at discontinuation of treatment and the initial NBS-TSH level < 45 µIU/mL as the best cut-off limits to predict TCH.

1 March 2022 in Turkish Archives of Pediatrics
Verified
Journal Article
Open access
ZDZeynep Donbaloğlu
Zeynep Donbaloğlu
HTHale Tuhan
Hale Tuhan
TTTuğce Tural-Kara
Tuğce Tural-Kara
ABAynur Bedel
Aynur Bedel
EÇEbru Barsal Çetiner
Ebru Barsal Çetiner
MPMesut Parlak
Mesut Parlak
Objective: This study aimed to evaluate presentations of new-onset type 1 diabetes mellitus in a pediatric cohort during the coronavirus disease 2019 pandemic. Materials and Methods: This study was designed as a single-center, descriptive, cross-sectional retrospective study. The patients diagnosed with new-onset type 1 diabetes mellitus between April 1, 2020, and April 1, 2021, were included in the study. The rate of severe acute respiratory syndrome coronavirus 2 polymerase chain reactivity-positivity was investigated. The pandemic period was compared with the same period of the pre-pandemic 2 years in terms of number of new-onset type 1 diabetes mellitus patients, rate of presentation with diabetic ketoacidosis, and degree of diabetic ketoacidosis severity. Results: In total, 56 patients were diagnosed with type 1 diabetes mellitus during the pandemic and 2 (3.57%) of them tested positive for severe acute respiratory syndrome coronavirus 2 polymerase chain reaction. The number of new-onset type 1 diabetes mellitus patients was 39 in 2019 and 39 in 2018. The rate of presentation with diabetic ketoacidosis was similar in the pandemic period compared to the pre-pandemic periods (53.5% in 2020 vs. 56.4% in 2019 and 53.8% in 2018; P = .94). The proportion of severe diabetic ketoacidosis was also similar in all years, respectively (43.3% in 2020 vs. 45.4% in 2019 and 47.6% in 2018; P = .95). Conclusion: We reported only 2 cases that tested positive for severe acute respiratory syndrome coronavirus 2among the new-onset type 1 diabetes mellitus patients during the pandemic. Although we found an increase in the number of new-onset type 1 diabetes mellitus cases by comparing with prepandemic period, rates of diabetic ketoacidosis and severe diabetic ketoacidosis were similar. There was no finding to suggest that severe acute respiratory syndrome coronavirus 2taking a part in type 1 diabetes mellitus pathogenesis. Since the development of type 1 diabetes mellitus is a long process, prospective studies are needed to investigate the long-term effects of severe acute respiratory syndrome coronavirus 2. Cite this article as: Donbaloğlu Z, Tuhan H, Tural Kara T, et al. The examination of the relationship between COVID-19 and new-onset type 1 diabetes mellitus in children. Turk Arch Pediatr. 2022;57(2):222-227.

19 March 2025 in Journal of Clinical Research in Pediatric Endocrinology
Verified
Journal Article
Open access
BSBerna Singin
Berna Singin
ZDZeynep Donbaloğlu
Zeynep Donbaloğlu
EÇEbru Barsal Çetiner
Ebru Barsal Çetiner
ABAynur Bedel
Aynur Bedel
KÇKürşat Çetin
Kürşat Çetin
MPMesut Parlak
Mesut Parlak
Xp21 Contiguous Gene Deletion Syndrome: Diagnosis, Treatment, and a Review of the Literature on a Rare Genetic Disorder - Journal of Clinical Research in Pediatric Endocrinology

2 May 2025 in Turkish Archives of Pediatrics
Verified
Journal Article
Open access
EÇEbru Barsal Çetiner
Ebru Barsal Çetiner
ZDZeynep Donbaloğlu
Zeynep Donbaloğlu
BSBerna Singin
Berna Singin
KÇKürşat Çetin
Kürşat Çetin
YBYasemin Funda Bahar
Yasemin Funda Bahar
MPMesut Parlak
Mesut Parlak
Objective: Growth hormone neurosecretory dysfunction (GH-NSD) is a rare cause of short stature. Diagnosis is established by evaluating nocturnal growth hormone secretion in patients with normal growth hormone stimulation tests. The aim of this study was to evaluate the first- and second-year treatment responses and final height in patients diagnosed with GH-NSD and treated with recombinant human growth hormone (rhGH). Materials and Methods: This retrospective study examined 500 patients treated with rhGH for short stature at a pediatric endocrinology clinic at Akdeniz University. Among them, 18 patients diagnosed with GH-NSD were included in the study. At the time of treatment initiation, parameters such as insulin-like growth factor 1 (IGF-1), growth hormone (GH) stimulation test results, mean GH level during sleep, height standard deviation score (SDS), mid-parental height (MPH), and predicted adult height (PAH) were assessed. Treatment responses during the first and second years, as well as final height data, were analyzed. Results: GH therapy improved height velocity (HV) and overall height. The mean baseline height SDS of the patients was −3.13 ± 0.36. In the first year, Δheight SDS was 0.72 ± 0.44, and in the second year, Δheight SDS was 1.00 ± 0.70. Patients who reached their final height had a mean height SDS of −1.72 ± 0.83 and Δheight SDS of 1.46 ± 0.62. A correlation was found between the baseline height SDS, PAH SDS, MPH SDS, and first-year HV. Conclusion: Patients with GH-NSD treated with rhGH respond well to treatment, achieving genetic height potential. Cite this article as: Çetiner EB, Donbaloğlu Z, Singin B, et al. Growth hormone therapy in neurosecretory dysfunction. Turk Arch Pediatr. 2025;60(3):294-300.

26 December 2024 in Journal of Clinical Research in Pediatric Endocrinology
Verified
Journal Article
Open access
BSBerna Singin
Berna Singin
ZDZeynep Donbaloğlu
Zeynep Donbaloğlu
EÇEbru Barsal Çetiner
Ebru Barsal Çetiner
KÇKürşat Çetin
Kürşat Çetin
NZNurten Özkan Zarif
Nurten Özkan Zarif
MPMesut Parlak
Mesut Parlak
Pseudohypoaldosteronism (PHA) is a rare disorder that, if not promptly recognized and treated, can lead to life-threatening hyperkalemia resulting in cardiac arrest and death. Systemic PHA is caused by variants that deactivate the epithelial sodium channel (ENaC) subunits. Management is challenging due to high-dose oral replacement therapy, and patients with systemic PHA require lifelong treatment. Here, we present the clinical course of a newborn diagnosed with PHA at 7 days of age due to severe dehydration, inadequate feeding, vomiting, and lethargy. The patient was found to be homozygous for the variant c.1234dup (p.Glu412Glyfs*39) in exon 8 of the SCNN1B gene. The patient had multiple hospitalizations during follow-up and died at the age of 10 months due to pneumonia. Maintaining a high clinical suspicion for PHA is crucial for initiating treatment and preventing potential cardiac arrest and death in these patients. Further research is needed to determine the significance of such novel mutations in this disease.

12 January 2025 in Journal of Health Sciences and Medicine
Verified
Journal Article
Open access
PDF file
ZDZeynep Donbaloğlu
Zeynep Donbaloğlu
BSBerna Singin
Berna Singin
EÇEbru Barsal Çetiner
Ebru Barsal Çetiner
ABAynur Bedel
Aynur Bedel
BBBilge Aydın Behram
Bilge Aydın Behram
MPMesut Parlak
Mesut Parlak
Aims: Our objective is to explore changes in body fat distribution and muscle strength among a cohort of girls with idiopathic central precocious puberty (ICPP) undergoing the gonadotropin-releasing hormone analogs (GnRHa) therapy. Methods: A total of 50 patients who were newly diagnosed with ICPP and treated with GnRHa were included in the study. Patients were investigated at baseline, 6th months and 12th months. Results: Body-mass index (BMI) standard deviation score (SDS) was similar throughout the treatment duration. The percentage of body fat (PBF) increased from 24.2±5.1% at the beginning to 26.3±5.3% at the 6th month and to 27.7±5.43% at the 12th month (p